Colorectal Cancer: Catching It Early

| January 8, 2018

article image
Colorectal cancer is one of the most common types of cancer and is a leading cause of cancer-related deaths in the United States. If all adults 45 and older were screened for colorectal cancer we could avoid thousands of deaths each year and prevent many people from ever getting the disease.

Spotlight

Myoderm

For nearly 30 years, Myoderm has been a specialist in global clinical trial supply, with deep expertise in sourcing, management, and labeling of commercial drugs and supplies. Our ingenuity, strategic thinking, and obsession with providing the most efficient, effective, and seamless supply solutions is why top pharmaceutical companies, biotech companies, CROs, and clinical trial packagers around the world rely on Myoderm for their supply needs. With headquarters in Europe and North America, and an extensive global network of manufacturers and suppliers, we pride ourselves on our proven ability to locate branded, generic and OTC products in all therapeutic classes and dosage forms – including the most hard-to-find medications. And, we are fully licensed for the storage and distribution of prescription medications including controlled drugs.

OTHER ARTICLES

Top Specialty Pharmacy Therapy Areas

Article | March 16, 2020

Accelerated by advancements in cancer treatments and a growing emphasis on personalized and precision medicine, specialty pharmacy represents a rapidly growing sector within the healthcare industry. In fact, the market is projected to grow to $500 billion by the end of this year—up from $200 billion in total U.S. specialty drug spending in 2017. Industry growth of this magnitude creates challenges for those looking to understand and penetrate the market. It can be difficult, after all, to maintain updated information about high-priority drug therapy areas or facility affiliations in a market that’s constantly changing.

Read More

Pfizer Won’t Win the Coronavirus Pharma War

Article | March 6, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

What are the advantages of PCD Pharma Company?

Article | February 17, 2020

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | April 17, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Spotlight

Myoderm

For nearly 30 years, Myoderm has been a specialist in global clinical trial supply, with deep expertise in sourcing, management, and labeling of commercial drugs and supplies. Our ingenuity, strategic thinking, and obsession with providing the most efficient, effective, and seamless supply solutions is why top pharmaceutical companies, biotech companies, CROs, and clinical trial packagers around the world rely on Myoderm for their supply needs. With headquarters in Europe and North America, and an extensive global network of manufacturers and suppliers, we pride ourselves on our proven ability to locate branded, generic and OTC products in all therapeutic classes and dosage forms – including the most hard-to-find medications. And, we are fully licensed for the storage and distribution of prescription medications including controlled drugs.

Events